Advances in HCV viral load testing
Gavin Cloherty; Abbott Molecular, USA

Multiple approaches for a common goal
Douglas Dieterich; Mount Sinai School of Medicine, USA

Gaps in future HCV therapies
Michael Fried; University of North Carolina at Chapel Hill, USA

Resistance in the age of HCV protease inhibitor/pegIFN/RBV therapy
Ann Kwong; Vertex Pharmaceuticals, USA

The host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance both in vitro and in HCV patients with no cross-resistance to DAAs
Kai Lin; Novartis, USA

Combination DAA strategies to cure HCV
Douglas Mayers; Idenix Pharmaceuticals, USA

Interferon free therapy for HCV
David Nelson; University of Florida, USA

Boceprevir in the era of DAA
Fred Poordad; Cedars-Sinai Medical Center, USA

STATE OF THE ART PRESENTATIONS
Exploitation of Host Cell Targets for HCV-specific Therapy
Ralf Bartenschlager; University of Heidelberg, Germany

Hepatitis Viruses: Evolution and Diversity
R. Palmer Beasley; Ashbel Smith Professor at The University of Texas School of Public Health, USA

The Future of HCV Therapy in Non-genotype 1 Patients
Marc Bourlière; Fondation Hôpital Saint Joseph, France

IL28B - Impact on Treatment Decisions
Michael Fried; University of North Carolina at Chapel Hill, USA

Best Targets for Antifibrotic Therapy
Scott Friedman; Mount Sinai School of Medicine, USA

HBV and HCV Antiviral Drug Resistance: Prevention and Monitoring
Stephen Locarnini; VIDRL, Australia

New In Vitro and In Vivo Preclincal Models for HCV Drug Discovery
Charles Rice; The Rockefeller University, USA

Turning Despair into Hope: Ripples becoming Tsunamis
Eugene Schiff; University of Miami, USA

HCV and the Central Nervous System
Howard Thomas; Imperial College, UK

Strategies for Improving Early Identification of Patients with Chronic Viral Hepatitis
Miriam Alter; University of Texas Medical Branch at Galveston, USA

Hepatitis B Foundation Symposium Debate: Are New Drugs Needed to Prevent HBV?
Timothy Block; Hepatitis B Foundation and Drexel University College of Medicine, USA (Moderator)
Frank Chisari; The Scripps Research Institute, USA (Co-moderator)
Adrian DiBisceglie; Saint Louis University School of Medicine, USA
Jules Dienstag; Harvard Medical School, USA
Brian McMahon; Alaska Native Medical Center, USA
David Thomas; Johns Hopkins University School of Medicine, USA

Intercellular Exosomal Transfer of HCV RNA to Plasmacytoid Dendritic Cells Triggers the Innate Response
Frank Chisari; The Scripps Research Institute, USA

Boceprevir and Telaprevir: Benefits and Limitations
Jules Dienstag; Harvard Medical School, USA

Panel Discussion: The Business of Antiviral Agents: Paying for Performance
Abel De La Rosa; Pharmasset, USA (Moderator)
David Witzke; PioneerPath Capital, USA (Moderator)

Poster Overviews
Adrian Di Bisceglie; Saint Louis University School of Medicine, USA
Adrian Ray; Gilead Sciences, Inc., USA

Will Lambda Interferon replace Pegs?
Douglas Dieterich; Mount Sinai School of Medicine, USA

Autophagy Machinery is Required to Initiate Hepatitis C Virus Replication
Marlène Dreux; The Scripps Research Institute, USA

Complete Replication Cycle Screening for Antiviral Discovery
Juliane Gentzsch; Twincore, Germany

Role of DAA in persons considered for liver transplantation
Ira Jacobson; Weill Cornell Medical College, USA

Mechanism of action of nitazoxanide
Brent Korba; Georgetown University, USA

TLR7: A Therapeutic Target for HBV and HCV Chronic Infections
Robert Lanford; Texas Biomedical Research Institute, USA

Fitness of protease inhibitor-resistant HCV variants
Stanley Lemon; University of North Carolina at Chapel Hill, USA

Eradication of HBV: Can We Eliminate cccDNA?
Massimo Levrero; Sapienza Università di Roma, Italy

Intrinsic Innate Immunity and HCV Infection
T. Jake Liang; NIDDK, National Institutes of Health, USA

HCV NS5A Inhibitors
Anna Lok; University of Michigan Medical Center, USA

HBV therapy: The role of quantitative HBsAg and cccDNA in future therapies
Patrick Marcellin; Hôpital Beaujon, France

Molecular Targeting Therapy for Our Patients with HCC
Masao Omata; University of Tokyo, Yamanashi Central Hospital, Japan

HCV viral kinetics in the age of DAAs
Alan Perelson; Los Alamos National Laboratory, USA

HIV/HCV Co-infected People: What are the Specific Concerns Co-infected People Face?
Marion Peters; University of California, San Francisco, USA

Management of Hepatitis C in the Era of DAA: Lessons Learned from Failed Studies
Paul Pockros; The Scripps Clinic, USA

The Status of Noninvasive Tests for Hepatic Fibrosis
Thierry Poynard; Groupe Hospitalier Pitie-Salpétriére, France

Roles of virus-host interaction in replication and pathogenesis of HCV
Glenn Randall; The University of Chicago, USA

Consensus Recommendation on Treatment of Acute HCV in HIV+ People, Ideas for Trials
Jürgen Rockstroh; University of Bonn, Germany

Acute hepatitis C infection in HIV-infected patients
Kenneth Sherman; University of Cincinnati College of Medicine, USA

Safety and Efficacy of PR+DAA in HCV/HIV Co-infected Patients
Mark Sulkowski; Johns Hopkins University, USA

Hepatitis B Foundation Symposium Debate: HCV, HBV, HIV and health care workers: updating guidelines in the age of antiviral agents
Tracy Swan; Treatment Action Group, USA (Moderator)
Joan Block; Hepatitis B Foundation, USA (Co-moderator)
Jules Levin; NATAP, USA
Anna Lok; University of Michigan Medical Center, USA
David Thomas; Johns Hopkins University School of Medicine, USA
John Ward; Centers for Disease Control and Prevention, USA

Special Lecture: Re-emergence of HDV
John Taylor; Fox Chase Cancer Center, USA

Hepatitis C Pharmacogenomics
David Thomas; Johns Hopkins, USA

Identification, Screening and Surveillance of HCV Infections in the Era of Improved Therapy for Hepatitis C
John Ward; Centers for Disease Control and Prevention, USA

Impact and Implementation of the WHO Resolution for Viral Hepatitis
Steve Wiersma; World Health Organization, Switzerland

Antiviral HBV Assembly Effectors (AEs): Mechanisms and Implications for Eradication
Adam Zlotnick; Indiana University, USA

Addressing an epidemic: San Francisco Hep B Free
Janet Zola; San Francisco Dept. of Public Health, USA